EUSA Pharma's Fotivda, or tivozanib, was approved by the European Commission as a first-line treatment for adult patients with advanced renal cell carcinoma and for those who are vascular endothelial growth factor and mTOR pathway inhibitor naive and whose disease progressed after previous treatment with cytokine therapy. The approval was based on a late-stage trial result in which the drug showed 11.9 months versus 9.1 months of progression-free survival in the overall patient population and 12.7 months versus 9.1 months in treatment-naive patients compared with Nexavar.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.